公开(公告)号：EP2605783A1

公开(公告)日：2013-06-26

申请号：EP11748282.8

申请日：2011-08-19

申请人： Lauer, Ulrich M. ,  Bitzer, Michael ,  Lampe, Johanna ,  Zimmermann, Martina ,  Berchtold, Susanne ,  Lange, Sebastian ,  Neubert, Wolfgang J. ,  Bossow, Sascha

发明人： Lauer, Ulrich M. ,  Bitzer, Michael ,  Lampe, Johanna ,  Zimmermann, Martina ,  Berchtold, Susanne ,  Lange, Sebastian ,  Neubert, Wolfgang J. ,  Bossow, Sascha

IPC分类号： A61K35/76 ,  C12N15/45 ,  A61P35/00 ,  C12N9/10 ,  C12N9/78 ,  C07K19/00

CPC分类号： A61K35/768 ,  A61K31/7088 ,  C07K2319/00 ,  C12N7/00 ,  C12N9/1077 ,  C12N9/78 ,  C12N2760/18421 ,  C12N2760/18432 ,  C12N2760/18443 ,  C12N2760/18471 ,  C12N2830/60 ,  C12Y305/04001

摘要： The present invention pertains to a pharmaceutical composition comprising a recombinant measles virus encoding a suicide gene for use in the treatment of malignant cells with primary or secondary resistances against an oncolytic measles virus without suicide gene activity. Further, the present invention pertains to a recombinant measles virus based on measles vaccine strain Schwarz encoding a suicide gene, which comprises a fusion of a cytosine deaminase, particularly yeast cytosine deaminase, and a uracil phosphoribosyltransferase, particularly yeast uracil phosphoribosyltransferase, to a method and a kit for preparing the recombinant measles virus as claimed herein.

公开(公告)号：EP2605783B1

公开(公告)日：2015-03-25

申请号：EP11748282.8

申请日：2011-08-19

申请人： Lauer, Ulrich M. ,  Bitzer, Michael ,  Lampe, Johanna ,  Zimmermann, Martina ,  Berchtold, Susanne ,  Lange, Sebastian ,  Neubert, Wolfgang J. ,  Bossow, Sascha

发明人： Lauer, Ulrich M. ,  Bitzer, Michael ,  Lampe, Johanna ,  Zimmermann, Martina ,  Berchtold, Susanne ,  Lange, Sebastian ,  Neubert, Wolfgang J. ,  Bossow, Sascha

IPC分类号： A61K35/76 ,  C12N15/45 ,  A61P35/00 ,  C12N9/10 ,  C12N9/78 ,  C07K19/00

CPC分类号： A61K35/768 ,  A61K31/7088 ,  C07K2319/00 ,  C12N7/00 ,  C12N9/1077 ,  C12N9/78 ,  C12N2760/18421 ,  C12N2760/18432 ,  C12N2760/18443 ,  C12N2760/18471 ,  C12N2830/60 ,  C12Y305/04001

摘要： The present invention pertains to a pharmaceutical composition comprising a recombinant measles virus encoding a suicide gene for use in the treatment of malignant cells with primary or secondary resistances against an oncolytic measles virus without suicide gene activity. Further, the present invention pertains to a recombinant measles virus based on measles vaccine strain Schwarz encoding a suicide gene, which comprises a fusion of a cytosine deaminase, particularly yeast cytosine deaminase, and a uracil phosphoribosyltransferase, particularly yeast uracil phosphoribosyltransferase, to a method and a kit for preparing the recombinant measles virus as claimed herein.